Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

NCT04074967 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma
Melanoma
Solid Tumor
Non-small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Phase Ib ARRY-614 + nivolumab
DRUG: Phase Ib ARRY-614 + nivolumab+ipilimumab
DRUG: Phase II ARRY-614 + nivolumab
DRUG: Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)
DRUG: Phase II ARRY-614 + nivolumab+ipilimumab (RCC)

Sponsor

Dan Zandberg

Collaborators

[object Object]